Published in J Natl Cancer Inst on November 18, 2013
Why sleep is important for health: a psychoneuroimmunology perspective. Annu Rev Psychol (2014) 1.41
Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst (2014) 1.34
Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer. PLoS One (2014) 1.05
Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Gynecol Oncol (2014) 1.01
Body mass index, physical activity, and serum markers of inflammation, immunity, and insulin resistance. Cancer Epidemiol Biomarkers Prev (2014) 1.01
Cognitive Behavioral Therapy and Tai Chi Reverse Cellular and Genomic Markers of Inflammation in Late-Life Insomnia: A Randomized Controlled Trial. Biol Psychiatry (2015) 0.99
Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin Transl Med (2015) 0.95
Validation of a blood protein signature for non-small cell lung cancer. Clin Proteomics (2014) 0.95
Dietary inflammatory index and risk of lung cancer and other respiratory conditions among heavy smokers in the COSMOS screening study. Eur J Nutr (2015) 0.90
Dietary magnesium and inflammation. Eur J Clin Nutr (2014) 0.90
A combined prognostic serum interleukin-8 and interleukin-6 classifier for stage 1 lung cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. J Thorac Oncol (2014) 0.87
Association between serum C-reactive protein value and prognosis of patients with non-small cell lung cancer: a meta-analysis. Int J Clin Exp Med (2015) 0.85
A prospective follow-up study of the relationship between C-reactive protein and human cancer risk in the Chinese Kailuan Female Cohort. Cancer Epidemiol Biomarkers Prev (2014) 0.85
Associations of Coffee Drinking with Systemic Immune and Inflammatory Markers. Cancer Epidemiol Biomarkers Prev (2015) 0.81
Identification of plasma protein markers common to patients with malignant tumour and Abnormal Savda in Uighur medicine: a prospective clinical study. BMC Complement Altern Med (2015) 0.81
Variation in Cancer Incidence among Patients with ESRD during Kidney Function and Nonfunction Intervals. J Am Soc Nephrol (2015) 0.81
Urinary protein biomarkers in the early detection of lung cancer. Cancer Prev Res (Phila) (2014) 0.81
Small cell lung cancer: Recruitment of macrophages by circulating tumor cells. Oncoimmunology (2015) 0.80
Dietary inflammatory index as a potential determinant of a length of hospitalization among surgical patients treated for colorectal cancer. Eur J Clin Nutr (2014) 0.79
The chemokine CXCL13 in lung cancers associated with environmental polycyclic aromatic hydrocarbons pollution. Elife (2015) 0.79
Plasma C-reactive protein and risk of breast cancer in two prospective studies and a meta-analysis. Cancer Epidemiol Biomarkers Prev (2015) 0.79
Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev (2015) 0.79
Laparoscopic surgery for colorectal cancer is not associated with an increase in the circulating levels of several inflammation-related factors. Cancer Biol Ther (2015) 0.78
Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis. Mol Cancer (2016) 0.77
Cancer prevention in HIV-infected populations. Semin Oncol (2015) 0.77
Clinical significance of serum thymus and activation-regulated chemokine in gastric cancer: potential as a serum biomarker. Cancer Sci (2014) 0.77
Application of multiplex arrays for cytokine and chemokine profiling of bile. Cytokine (2015) 0.77
The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort study. Infect Agent Cancer (2015) 0.77
Using Immune Marker Panels to Evaluate the Role of Inflammation in Cancer: Summary of an NCI-sponsored Workshop. Cancer Epidemiol Biomarkers Prev (2015) 0.77
Metabolic serum biomarkers for the prediction of cancer: a follow-up of the studies conducted in the Swedish AMORIS study. Ecancermedicalscience (2015) 0.77
Age- and Sex-Associated Effects on Acute-Phase Proteins in Göttingen Minipigs. Comp Med (2015) 0.76
A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II. Cancer Epidemiol Biomarkers Prev (2014) 0.76
Clinical and computed tomography findings in Chinese lung cancer patients with HIV infection: A multi-center study. Thorac Cancer (2017) 0.75
Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan. Sci Rep (2016) 0.75
Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease. Clin Transl Immunology (2016) 0.75
Myeloid STAT3 promotes lung tumorigenesis by transforming tumor immunosurveillance into tumor-promoting inflammation. Cancer Immunol Res (2017) 0.75
Cancer Risk in Patients With Empyema: A Nationwide Population-Based Study. Medicine (Baltimore) (2016) 0.75
Reducing the burden of obesity-associated cancers with anti-inflammatory long-chain omega-3 polyunsaturated fatty acids. Prostaglandins Other Lipid Mediat (2016) 0.75
Immune oppression array elucidating immune escape and survival mechanisms in uveal melanoma. Int J Ophthalmol (2016) 0.75
Serum Cytokinome Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays. Mediators Inflamm (2016) 0.75
The Dietary Inflammatory Index Is Associated with Prostate Cancer Risk in French Middle-Aged Adults in a Prospective Study. J Nutr (2016) 0.75
Effect of serum interleukin-1 receptor antagonist level on survival of patients with non-small cell lung cancer. Mol Clin Oncol (2017) 0.75
MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinoma. Oncotarget (2016) 0.75
High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer. PLoS One (2017) 0.75
The prognostic value of neutrophil to lymphocyte and platelet to lymphocyte ratios for patients with lung cancer. Oncol Lett (2017) 0.75
Association between a Single Donor TARC/CCL17 Promotor Polymorphism and Obstructive Chronic Lung Allograft Dysfunction after Lung Transplantation. Front Immunol (2017) 0.75
Associations between self-reported diabetes and 78 circulating markers of inflammation, immunity, and metabolism among adults in the United States. PLoS One (2017) 0.75
Identification of relevant prognostic values of cytokeratin 20 and cytokeratin 7 expressions in lung cancer. Biosci Rep (2017) 0.75
Inflammation and cancer. Nature (2002) 53.78
Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med (2011) 38.61
Immunity, inflammation, and cancer. Cell (2010) 28.27
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 10.99
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
Lung cancer in never smokers: a review. J Clin Oncol (2007) 5.49
Variations in lung cancer risk among smokers. J Natl Cancer Inst (2003) 5.00
Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res (2007) 4.39
A risk model for prediction of lung cancer. J Natl Cancer Inst (2007) 4.25
Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med (2000) 3.36
Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev (2005) 3.20
Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst (2011) 2.61
Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol (2009) 2.61
Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst (2011) 2.31
The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol (2006) 1.95
C-reactive protein and risk of lung cancer. J Clin Oncol (2010) 1.90
Mechanisms of disease: Inflammation and the origins of cancer. Nat Clin Pract Oncol (2005) 1.88
The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer (2003) 1.88
Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res (2007) 1.82
Chronic obstructive lung diseases and risk of non-small cell lung cancer in women. J Thorac Oncol (2009) 1.74
A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening. J Thorac Oncol (2012) 1.63
Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res (2011) 1.63
Evaluation of multiplexed cytokine and inflammation marker measurements: a methodologic study. Cancer Epidemiol Biomarkers Prev (2011) 1.60
Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk. Cancer (2012) 1.58
Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study. PLoS One (2009) 1.56
Lung cancer risk prediction: a tool for early detection. Int J Cancer (2007) 1.51
Previous pulmonary diseases and risk of lung cancer in Gansu Province, China. Int J Epidemiol (2001) 1.46
Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. Clin Chem (2008) 1.34
The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med (2007) 1.26
Chlamydia pneumoniae infection and risk of lung cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.18
Progression of airway dysplasia and C-reactive protein in smokers at high risk of lung cancer. Am J Respir Crit Care Med (2005) 1.09
Chlamydia pneumoniae infection and risk for lung cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.07
Tuberculosis and subsequent risk of lung cancer in Xuanwei, China. Int J Cancer (2009) 1.07
C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis. PLoS One (2012) 1.05
Increased risk of lung cancer in men with tuberculosis in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev (2011) 1.05
Circulating markers of interstitial lung disease and subsequent risk of lung cancer. Cancer Epidemiol Biomarkers Prev (2011) 0.96
Cryptogenic fibrosing alveolitis and lung cancer: the BTS study. Thorax (2009) 0.96
Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer. Cancer Immunol Immunother (2006) 0.94
Variants in inflammation genes are implicated in risk of lung cancer in never smokers exposed to second-hand smoke. Cancer Discov (2011) 0.92
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol (2008) 7.97
Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS (2006) 7.08
Prediction error estimation: a comparison of resampling methods. Bioinformatics (2005) 6.41
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Prevalence of oral HPV infection in the United States, 2009-2010. JAMA (2012) 6.02
On criteria for evaluating models of absolute risk. Biostatistics (2005) 5.71
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet (2009) 5.62
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol (2013) 5.40
Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99
Kernel stick-breaking processes. Biometrika (2008) 4.96
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
Quality control and quality assurance in genotypic data for genome-wide association studies. Genet Epidemiol (2010) 4.83
The carcinogenicity of human papillomavirus types reflects viral evolution. Virology (2005) 4.72
Merkel cell carcinoma and HIV infection. Lancet (2002) 4.72
Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst (2011) 4.69
Pathway analysis by adaptive combination of P-values. Genet Epidemiol (2009) 4.48
Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med (2010) 4.30
B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med (2009) 4.27
MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A (2008) 4.06
Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer (2003) 4.02
Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst (2010) 3.95
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst (2011) 3.92
Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet (2010) 3.91
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One (2008) 3.87
Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis (2005) 3.84
Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood (2008) 3.81
Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst (2005) 3.75
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Selection criteria for lung-cancer screening. N Engl J Med (2013) 3.69
Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol (2008) 3.60
Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst (2009) 3.58
HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis (2007) 3.56
Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol (2002) 3.53
A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis (2005) 3.46
Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis (2011) 3.44
Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res (2008) 3.39
Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res (2005) 3.33
Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst (2008) 3.32
The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2011) 3.29
AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst (2007) 3.28
Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet (2013) 3.25
Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood (2005) 3.25
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine (2008) 3.17
Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst (2006) 3.17
HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer (2008) 3.16
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis (2013) 3.06
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation. Nat Immunol (2004) 2.96
Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc (2007) 2.91
Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood (2006) 2.90
Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol (2013) 2.87
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol (2011) 2.85
MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84
Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst (2010) 2.81
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst (2007) 2.70
Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst (2006) 2.67
Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer (2008) 2.67
Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov (2011) 2.66
Age-related crossover in breast cancer incidence rates between black and white ethnic groups. J Natl Cancer Inst (2008) 2.64
Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst (2011) 2.61
A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst (2005) 2.60
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck (2009) 2.59
Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst (2003) 2.58
MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst (2005) 2.57
Colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol (2008) 2.56
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood (2011) 2.54
Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA (2007) 2.51
Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood (2008) 2.49
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine (2008) 2.48
MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res (2010) 2.48
US lung cancer trends by histologic type. Cancer (2014) 2.46
Impact of occupational carcinogens on lung cancer risk in a general population. Int J Epidemiol (2012) 2.46
Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer (2004) 2.46
Leisure time physical activity of moderate to vigorous intensity and mortality: a large pooled cohort analysis. PLoS Med (2012) 2.45
Human herpesvirus 8 infection within families in rural Tanzania. J Infect Dis (2003) 2.42
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
BayesMendel: an R environment for Mendelian risk prediction. Stat Appl Genet Mol Biol (2004) 2.34
Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res (2006) 2.33
Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med (2010) 2.33